Navigation Links
C3i and Bristol-Myers Squibb to Discuss the Effects of Oracle Clinical 4.5.3 Zero Footprint on Support Services at the Oracle Health Sciences User Group Conference
Date:10/5/2010

SAN ANTONIO, Texas, Oct. 5 /PRNewswire/ -- C3i, the leader in technology services for the life sciences industry, and Bristol-Myers Squibb (BMS), a leading global biopharmaceutical company, will deliver a joint presentation discussing the advantages realized from upgrading to the newest version of Oracle Clinical/Remote Data Capture (OCRDC) software. The presentation will take place in October during the Oracle Health Sciences User Group conference (OHSUG) in San Antonio, TX October 10-13.

The presentation, titled "The Direct and Indirect Effects Upgrading to Zero Footprint has on Clinical Services", investigates several support areas of interest including site assessment, connectivity, laptop provisioning and software issues. Based on quantitative data gathered from BMS operations, Darlene Kalinowski, Associate Director, EDC Operations at BMS and Warren Ryanes, Account Director at C3i will demonstrate the benefits to clinical trial sponsors of upgrading to OCRDC 4.5.3. The "before" and "after" case study will show improvements in material, time and costs. The two presenters will highlight how a "zero footprint" and a decrease in 3rd party plug-ins results in cost savings in areas as diverse as shipping and connectivity, and in fewer support cases related to data entry, navigation, and reports.

"The Oracle Health Sciences User Group conference is a great place to exchange knowledge on Oracle products and related services .We are excited to share the positive experience of BMS with our colleagues from the industry," said Darlene Kalinowski. Warren Ryanes added: "BMS is a great partner. C3i is delighted to have the opportunity work with Darlene and her team to achieve such excellent results."

About C3i: Headquartered in Morristown, New Jersey, C3i Inc. has global operations centers in the United States, India and Bulgaria. Their 1000 employees provide consulting, systems implementation, technology training, multi-lingual help desk, hardware provisioning and break/fix, asset management, hosting, and user/application administration services for pharmaceutical companies worldwide. To learn more, visit www.c3i-inc.com and follow us on Twitter at http://twitter.com/C3i_Inc.

About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.Contact: Dave Hanaman C3i 973-401-4677 dhanaman@c3i-inc.com
'/>"/>

SOURCE C3i
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
4. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
5. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
6. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
7. [video] Jacques Tizabi, CEO of Universal Detection Technology Discusses Latest Purchase Order on WallSt.nets 3-Minute Press Show
8. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
9. VentriPoint Diagnostics Files Management Discussion and Analysis, Unaudited Financial Results for 2Q 2008
10. Anesiva Announces Conference Call and Webcast to Discuss Updates to Corporate Strategy and Milestones
11. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec 5, 2016 Research and ... "Biomarkers - Technologies, Markets and Companies" to their offering. ... , , ... their discovery using various -omics technologies such as proteomics and metabolomics. ... new tests are also based on biomarker. Currently the ...
(Date:12/5/2016)... 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the ... and Safety Monitoring Board (DSMB) for the Company,s ... (CVD) patients has completed a second planned safety ... as planned without any modifications. The DSMB reviewed ... or efficacy concerns were identified. The DSMB will ...
(Date:12/4/2016)... ... December 02, 2016 , ... A proposed five-year extension ... federally funded research and development is welcome news for the photonics community, say ... , As part of the National Defense Authorization Act (NDAA) compromise agreement finalized ...
(Date:12/2/2016)... 2016 More than $4.3 million was raised last ... DHMD ). The gala was held at the American Museum ... and honored Alan Alda and ... and medicine and the public understanding of science. Since the ... event has raised $40 million for the Laboratory,s research and ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
Breaking Biology News(10 mins):